L
Luis M. Ruilope
Researcher at European University of Madrid
Publications - 891
Citations - 109166
Luis M. Ruilope is an academic researcher from European University of Madrid. The author has contributed to research in topics: Blood pressure & Renal function. The author has an hindex of 94, co-authored 841 publications receiving 97778 citations. Previous affiliations of Luis M. Ruilope include Lund University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Guidelines Updates in the Treatment of Obesity or Metabolic Syndrome and Hypertension
TL;DR: Intensive management of all the risk factors of the metabolic syndrome is also needed to reduce body weight and waist circumference, lessen insulin resistance and avoid the development of new-onset diabetes and cardiovascular disease associated with this entity.
Journal Article
INSIGHT: international nifedipine GITS study intervention as a goal in hypertension treatment.
Morris J. Brown,Alain Castaigne,Luis M. Ruilope,G. Mancia,Talma Rosenthal,P. W. De Leeuw,F Ebner +6 more
TL;DR: The objective of the study is to compare fatal and nonfatal cardiovascular endpoints in hypertensive patients randomised to the calcium-channel blocker, nifedipine GITS or a thiazide diuretic, co-amilozide.
Journal ArticleDOI
Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria
Laura Gonzalez-Calero,Paula J. Martinez,Marta Martin-Lorenzo,Montserrat Baldan-Martin,Gema Ruiz-Hurtado,Fernando de la Cuesta,E. Calvo,Julian Segura,Juan Antonio López,Jesús Vázquez,Maria G. Barderas,Luis M. Ruilope,Fernando Vivanco,Gloria Alvarez-Llamas +13 more
TL;DR: Exosomal protein alterations in hypertensive patients with albuminuria in the presence of chronic RAS suppression are examined to find novel clues underlying its development and constitute potential targets for drug development.
Journal ArticleDOI
Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials.
TL;DR: The need for future research into metabolic syndrome is assessed and whether clinical surrogates for CV end points, such as new onset diabetes, should be included in clinical trials of new drugs, new regimens, or new indications is discussed.
Journal ArticleDOI
Pressure Natriuresis in Nitric Oxide-Deficient Hypertensive Rats Effect of Antihypertensive Treatments
Lourdes A. Fortepiani,Elena Rodrigo,M. Clara Ortiz,Victoria Cachofeiro,Noemí M. Atucha,Luis M. Ruilope,Vicente Lahera,Joaquín García-Estañ +7 more
TL;DR: The results indicate that interruption or blockade of the renin-angiotensin system and calcium channel blockade are effective treatments for the NO-deficient arterial hypertension and renal vasoconstriction.